Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EPR Properties (EPR) vs Heron Therapeutics Inc (HRTX) Price & Performance

EPR PropertiesTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

EPR Properties vs Heron Therapeutics Inc — how do they compare? EPR Properties trades at $60.2 (market cap $4.58B), while Heron Therapeutics Inc trades at $0.33 (market cap $61.47M). The key difference: EPR Properties is far larger — about 74.5× Heron Therapeutics Inc's market cap, and EPR Properties pays a 6.22% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

EPRHRTX
Market Cap
$4.58B$61.47M
Sector
Real EstateHealth
52-Week High
$64.32$1.49
52-Week Low
$48.71$0.32
Enterprise Value
$8.09B$168.21M
Dividend Yield
6.22%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EPR Properties

No Aura AI signal available yet.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About EPR Properties

EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.

Read more on EPR

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX